- Home
- EQX vs RCKT Comparison
EQX vs RCKT Comparison
Compare EQX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQX
- RCKT
- Stock Information
- Founded
- EQX 2007
- RCKT 1999
- Country
- EQX Canada
- RCKT United States
- Employees
- EQX N/A
- RCKT N/A
- Industry
- EQX Precious Metals
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- EQX Basic Materials
- RCKT Health Care
- Exchange
- EQX Nasdaq
- RCKT Nasdaq
- Market Cap
- EQX 3.2B
- RCKT 326.4M
- IPO Year
- EQX N/A
- RCKT N/A
- Fundamental
- Price
- EQX $5.81
- RCKT $2.95
- Analyst Decision
- EQX
- RCKT Buy
- Analyst Count
- EQX 0
- RCKT 13
- Target Price
- EQX N/A
- RCKT $18.50
- AVG Volume (30 Days)
- EQX 18.2M
- RCKT 4.3M
- Earning Date
- EQX 08-06-2025
- RCKT 08-04-2025
- Dividend Yield
- EQX N/A
- RCKT N/A
- EPS Growth
- EQX N/A
- RCKT N/A
- EPS
- EQX 0.64
- RCKT N/A
- Revenue
- EQX $1,696,526,000.00
- RCKT N/A
- Revenue This Year
- EQX $40.61
- RCKT N/A
- Revenue Next Year
- EQX $14.56
- RCKT N/A
- P/E Ratio
- EQX $14.36
- RCKT N/A
- Revenue Growth
- EQX 54.88
- RCKT N/A
- 52 Week Low
- EQX $4.48
- RCKT $2.19
- 52 Week High
- EQX $7.45
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- EQX 37.70
- RCKT 41.69
- Support Level
- EQX $5.66
- RCKT $2.40
- Resistance Level
- EQX $5.95
- RCKT $2.70
- Average True Range (ATR)
- EQX 0.20
- RCKT 0.21
- MACD
- EQX -0.05
- RCKT 0.15
- Stochastic Oscillator
- EQX 16.89
- RCKT 73.53
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.